ATOSSA THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Basic
ATOSSA THERAPEUTICS, INC. (ATOS) reported Net Income (Loss) Available to Common Stockholders, Basic of -$6.28 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2023-05-15
- ATOSSA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2023-03-31 was -$6.28M.
- ATOSSA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2022-09-30 was -$8.01M.
- ATOSSA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2022-06-30 was -$6.67M.
- ATOSSA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2022-03-31 was -$4.79M.
- ATOSSA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2021 was -$20.61M.
- ATOSSA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2020 was -$22.33M.
- ATOSSA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2019 was -$17.24M.
- ATOSSA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2018 was -$22.88M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-03-31 | -$6.28M 10-Q · filed 2023-05-15 | |||||||
| 2022-09-30 | -$8.01M 10-Q · filed 2022-11-07 | -$14.68M derived: sum of 2 quarters · filed 2022-11-07 | -$19.47M 10-Q · filed 2022-11-07 | -$24.30M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2022-06-30 | -$6.67M 10-Q · filed 2022-08-08 | -$11.46M 10-Q · filed 2022-08-08 | -$16.29M derived: sum of 3 quarters · filed 2023-05-15 | -$21.49M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2022-03-31 | -$4.79M 10-Q · filed 2023-05-15 | -$9.62M derived: sum of 2 quarters · filed 2023-05-15 | -$14.81M derived: sum of 3 quarters · filed 2023-05-15 | -$21.85M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | -$4.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$10.03M derived: sum of 2 quarters · filed 2022-11-07 | -$17.07M derived: sum of 3 quarters · filed 2022-11-07 | -$20.61M 10-K · filed 2022-02-28 | ||||
| 2021-09-30 | -$5.20M 10-Q · filed 2022-11-07 | -$5.20M 10-Q · filed 2021-11-15 | -$12.24M derived: sum of 2 quarters · filed 2022-11-07 | -$15.77M 10-Q · filed 2022-11-07 | -$15.77M 10-Q · filed 2021-11-15 | -$27.76M derived: sum of 4 quarters · filed 2022-11-07 | ||
| 2021-06-30 | -$7.04M 10-Q · filed 2022-08-08 | -$7.04M 10-Q · filed 2021-08-13 | -$10.58M 10-Q · filed 2022-08-08 | -$10.58M 10-Q · filed 2021-08-13 | -$22.56M derived: sum of 3 quarters · filed 2022-08-08 | -$26.05M derived: sum of 4 quarters · filed 2022-08-08 | ||
| 2021-03-31 | -$3.54M 10-Q · filed 2022-05-09 | -$3.54M 10-Q · filed 2021-05-14 | -$15.52M derived: sum of 2 quarters · filed 2022-05-09 | -$19.02M derived: sum of 3 quarters · filed 2022-05-09 | -$22.92M derived: sum of 4 quarters · filed 2022-05-09 | |||
| 2020-12-31 | -$11.99M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$15.48M derived: sum of 2 quarters · filed 2022-02-28 | -$19.38M derived: sum of 3 quarters · filed 2022-02-28 | -$22.33M 10-K · filed 2022-02-28 | -$22.33M 10-K · filed 2021-03-31 | |||
| 2020-09-30 | -$3.49M 10-Q · filed 2021-11-15 | -$7.40M derived: sum of 2 quarters · filed 2021-11-15 | -$10.34M 10-Q · filed 2021-11-15 | -$12.96M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | -$3.91M 10-Q · filed 2021-08-13 | -$6.85M 10-Q · filed 2021-08-13 | -$9.47M derived: sum of 3 quarters · filed 2021-08-13 | -$12.76M derived: sum of 4 quarters · filed 2021-08-13 | ||||
| 2020-03-31 | -$2.95M 10-Q · filed 2021-05-14 | -$5.57M derived: sum of 2 quarters · filed 2021-05-14 | -$8.85M derived: sum of 3 quarters · filed 2021-05-14 | -$16.11M derived: sum of 4 quarters · filed 2021-05-14 | ||||
| 2019-12-31 | -$2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$5.90M derived: sum of 2 quarters · filed 2021-03-31 | -$13.17M derived: sum of 3 quarters · filed 2021-03-31 | -$17.24M 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | -$3.29M 10-Q · filed 2020-11-13 | -$10.55M derived: sum of 2 quarters · filed 2020-11-13 | -$14.62M 10-Q · filed 2020-11-13 | -$16.70M derived: sum of 4 quarters · filed 2020-11-13 | ||||
| 2019-06-30 | -$7.26M 10-Q · filed 2020-08-13 | -$11.34M 10-Q · filed 2020-08-13 | -$13.41M derived: sum of 3 quarters · filed 2020-08-13 | -$16.72M derived: sum of 4 quarters · filed 2020-08-13 | ||||
| 2019-03-31 | -$4.07M 10-Q · filed 2020-05-13 | -$6.15M derived: sum of 2 quarters · filed 2020-05-13 | -$9.46M derived: sum of 3 quarters · filed 2020-05-13 | -$25.08M derived: sum of 4 quarters · filed 2020-05-13 | ||||
| 2018-12-31 | -$2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | -$5.39M derived: sum of 2 quarters · filed 2020-03-26 | -$21.01M derived: sum of 3 quarters · filed 2020-03-26 | -$22.88M 10-K · filed 2020-03-26 | ||||
| 2018-09-30 | -$3.31M 10-Q · filed 2019-11-13 | -$18.93M derived: sum of 2 quarters · filed 2019-11-13 | -$20.81M 10-Q · filed 2019-11-13 | -$22.80M derived: sum of 4 quarters · filed 2019-11-13 | ||||
| 2018-06-30 | -$15.62M 10-Q · filed 2019-08-13 | -$8.92M 10-Q · filed 2018-08-13 | -$17.50M 10-Q · filed 2019-08-13 | -$10.80M 10-Q · filed 2018-08-13 | -$19.49M derived: sum of 3 quarters · filed 2019-08-13 | -$21.67M derived: sum of 4 quarters · filed 2019-08-13 | ||
| 2018-03-31 | -$1.87M 10-Q · filed 2019-05-13 | -$3.87M derived: sum of 2 quarters · filed 2019-05-13 | -$6.05M derived: sum of 3 quarters · filed 2019-05-13 | -$10.86M derived: sum of 4 quarters · filed 2019-05-13 | ||||
| 2017-12-31 | -$1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | -$4.18M derived: sum of 2 quarters · filed 2019-03-28 | -$8.99M derived: sum of 3 quarters · filed 2019-03-28 | -$10.69M 10-K · filed 2019-03-28 | ||||
| 2017-09-30 | -$2.18M 10-Q · filed 2018-11-14 | -$6.99M derived: sum of 2 quarters · filed 2018-11-14 | -$8.70M 10-Q · filed 2018-11-14 | |||||
| 2017-06-30 | -$4.81M 10-Q/A · filed 2018-11-13 | -$6.51M 10-Q/A · filed 2018-11-13 | ||||||
| 2016-12-31 | -$2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$2.32M derived: sum of 2 quarters · filed 2018-03-08 | -$4.04M derived: sum of 3 quarters · filed 2018-03-08 | -$6.37M 10-K · filed 2018-03-08 | ||||
| 2016-09-30 | $204.69K 10-Q · filed 2017-11-13 | -$1.52M derived: sum of 2 quarters · filed 2017-11-13 | -$3.85M 10-Q · filed 2017-11-13 | |||||
| 2016-06-30 | -$1.72M 10-Q · filed 2017-08-14 | -$4.05M 10-Q · filed 2017-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |